Cost-effectiveness of camrelizumab plus rivoceranib for advanced liver cancer in China
Author Information
Author(s): Zhao Zhonghua, Jiang Xiongying, Wen Shiping, Hao Yanzhang
Primary Institution: Binzhou Medical University Hospital
Hypothesis
Is the combination of camrelizumab and rivoceranib more cost-effective than sorafenib for treating advanced hepatocellular carcinoma in different regions of China?
Conclusion
The combination of camrelizumab and rivoceranib is a cost-effective treatment option for advanced hepatocellular carcinoma across various regions in China.
Supporting Evidence
- The camrelizumab plus rivoceranib group had a QALY gain of 1.71 compared to 0.91 for the sorafenib group.
- The ICER for camrelizumab plus rivoceranib was $9,150.75 per QALY, which is below the willingness-to-pay thresholds.
- Probability of cost-effectiveness was 99.9% in medium-income regions and 100% in high-income regions.
Takeaway
This study shows that a new cancer treatment is not only better for patients but also costs less money in many parts of China.
Methodology
A Markov model was developed using data from the phase III CARES-310 clinical trial to assess cost-effectiveness.
Potential Biases
The study may be subject to biases related to the controlled treatment protocols of the clinical trial.
Limitations
The study's findings may not be generalizable due to strict eligibility criteria and the potential variability in drug pricing.
Participant Demographics
Patients included were those with Barcelona Clinic Liver Cancer stage B/C HCC, not previously treated with surgery or local methods.
Statistical Information
P-Value
9150.75
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website